Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
J Hepatol. 2013 Jan;58(1):58-64. doi: 10.1016/j.jhep.2012.08.017. Epub 2012 Aug 25.
BACKGROUND & AIMS: Although the Milan criteria (MC) have been used to select liver transplantation candidates among patients with hepatocellular carcinoma (HCC), many patients exceeding the MC have shown good prognosis. Preoperative neutrophil-lymphocyte ratio (NLR) is a predictor of patient prognosis, but its mechanism has never been clarified.
We assessed outcomes in 158 patients who had undergone living-donor liver transplantation (LDLT) for HCC. Recurrence-free survival (RFS) was determined in patients with high (≥ 4) and low (<4) NLR. Levels of expression of vascular endothelial growth factor (VEGF), interleukin (IL)-8, IL-17, CD68, and CD163 were measured.
The 5-year RFS rate was significantly lower in patients with high (n=26) than with low (n=132) NLR (30.3% vs. 89.0%, p<0.0001), in patients with high (n=15) than with low (n=79) NLR who met the MC (73.6% vs. 100%, p=0.0008) and in patients with high (n=11) than with low (n=53) NLR who exceeded the MC (0% vs. 76.1%, p=0.0002). Tumor expression of VEGF, IL8, IL-17, CD68, and CD163 was similar in the high and low NLR groups, but serum and peritumoral IL-17 levels were significantly higher in the high-NLR group (p=0.01 each). The density of peritumoral CD163 correlated with the density of peritumoral IL-17-producing cells (p=0.04) and was significantly higher in the high-NLR group (p=0.005).
NLR predicts outcomes after LDLT for HCC via the inflammatory tumor microenvironment. Combined with the MC, NLR may be a new criterion for LDLT candidates with HCC.
米兰标准(MC)被用于选择肝细胞癌(HCC)患者进行肝移植,但许多超出 MC 的患者预后良好。术前中性粒细胞与淋巴细胞比值(NLR)是预测患者预后的指标,但其中的机制尚未阐明。
我们评估了 158 例接受活体供肝移植(LDLT)治疗 HCC 的患者的结局。在 NLR 较高(≥4)和较低(<4)的患者中,分别确定无复发生存(RFS)。测量血管内皮生长因子(VEGF)、白细胞介素(IL)-8、IL-17、CD68 和 CD163 的表达水平。
NLR 较高(n=26)的患者 5 年 RFS 率明显低于 NLR 较低(n=132)的患者(30.3% vs. 89.0%,p<0.0001),NLR 较高(n=15)的患者 5 年 RFS 率明显低于符合 MC(n=79)的患者(73.6% vs. 100%,p=0.0008),也明显低于超出 MC(n=11)的患者(0% vs. 76.1%,p=0.0002)。高 NLR 组和低 NLR 组的肿瘤 VEGF、IL8、IL-17、CD68 和 CD163 表达相似,但高 NLR 组的血清和肿瘤周围 IL-17 水平显著较高(p=0.01 各)。肿瘤周围 CD163 的密度与肿瘤周围产生 IL-17 的细胞密度相关(p=0.04),并且在高 NLR 组中明显更高(p=0.005)。
NLR 通过炎症性肿瘤微环境预测 LDLT 治疗 HCC 的结局。与 MC 相结合,NLR 可能成为 HCC LDLT 候选者的新标准。